共 50 条
- [41] Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancerASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (06) : 343 - 352Gibson, Amanda J. W.D'Silva, AdrijanaElegbede, Anifat A.Tudor, Roxana A.Dean, Michelle L.Bebb, Dafydd GwynHao, Desiree
- [42] ll-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancerPHARMACOLOGICAL RESEARCH, 2023, 191Xu, CongJiang, Ze-BoShao, LeZhao, Zi-MingFan, Xing-XingSui, XinbingYu, Li-LiWang, Xuan-RunZhang, Ruo-NanWang, Wen-JunXie, Ya-JiaZhang, Yi-ZhongNie, Xiao-WenXie, ChunHuang, Ju-MinWang, JingWang, JueLeung, Elaine Lai-HanWu, Qi-Biao
- [43] Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancerLUNG CANCER, 2017, 111 : 65 - 68Tokaca, NadzaWotherspoon, AndrewNicholson, Andrew G.Fotiadis, NicosThompson, LisaPopat, Sanjay
- [44] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trialsEuropean Journal of Medical Research, 28Ruijian LiWeiyi LiFang ZhangShanshan Li
- [45] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trialsEUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)Li, RuijianLi, WeiyiZhang, FangLi, Shanshan
- [46] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitorsJOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949Dogan, IzzetKhanmammadov, NijatYildiz, AnilAhmed, Melin AydanVatansever, SezaiSaip, PinarAydiner, Adnan
- [47] Molecular and Cellular Heterogeneity Underpin Treatment Response Across a Spectrum of EGFR-Mutant Non-Small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S562 - S562Yuan, J.Lim, E.Ma, S. M.Chua, K. P.Lee, Y. F.Lim, M. J.Yeo, X. H.Phua, C.Takano, A.Aung, Z.Lim, K. H. T.Tan, E.Tan, D.Chew, G. L.Tam, W. L.
- [48] PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancerJAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (05) : 617 - 622Miyawaki, ErikoMurakami, HaruyasuMori, KeitaMamesaya, NobuakiKawamura, TakahisaKobayashi, HarukiOmori, ShotaWakuda, KazushigeOno, AkiraKenmotsu, HirotsuguNaito, TateakiTakahashi, Toshiaki
- [49] Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer CellsNEOPLASIA, 2016, 18 (02): : 111 - 120Saygideger-Kont, YaseminMinas, Tsion ZewduJones, HaydenHour, SarahCelik, HaydarTemel, IdilHan, JennyAtabey, NeseErkizan, Hayriye VerdaToretsky, Jeffrey A.Uren, Aykut
- [50] BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerSCIENTIFIC REPORTS, 2015, 5Karachaliou, NikiCodony-Servat, JordiTeixido, CristinaPilotto, SaraDrozdowskyj, AnaCodony-Servat, CariesGimenez-Capitan, AnaAngel Molina-Vila, MiguelBertran-Alamillo, JordiGervais, RadjMassuti, BartomeuMoran, TeresaMajem, MargaritaFelip, EnriquetaCarcereny, EnricGarcia-Campelo, RosarioViteri, SantiagoGonzalez-Cao, MariaMorales-Espinosa, DanielaVerlicchin, AlbertoCrisetti, ElisabettaChaib, ImaneSantarpia, MariacarmelaLuis Ramirez, JoseBosch-Barrera, JoaquimFelipe Cardona, Andresde Marinis, FilippoLopez-Vivanco, GuillermoMiguel Sanchez, JoseVergnenegre, AlainHernandez, Jose Javier SanchezSperduti, IsabellaBria, EmilioRosell, Rafael